Drugs / photosynthetic dermal regeneration matrices
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07157657 | Jun 2025 → May 2028 expected | chronic ulcer of skin | Pontificia Universidad Catolica de Chile | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | photosynthetic dermal regeneration matrices | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07157657 ↗ |
| Known as | PDRM | “photosynthetic dermal regeneration matrix (PDRM) is designed to create a more favorable microenvironment for tissue regeneration” NCT07157657 ↗ |
| Modality | Other / unclassified | “This photosynthetic dermal regeneration matrix (PDRM) is designed to create a more favorable microenvironment for tissue regeneration by enhancing local oxygen availability in situ.” NCT07157657 ↗ |
| Route | Other | “standard dermal regeneration matrices (DRMs) and photosynthetic dermal regeneration matrices (PDRMs), containing live photosynthetic microalgae, are implanted in separate wound areas” NCT07157657 ↗ |